Kevin M. Brennan, SVP, FINANCE AND ACCOUNTING at Xilio Therapeutics, Inc. (XLO), sold 1,803 shares at $0.98 ($2K) on 2025-01-02, disclosed to the SEC on 2025-01-03.
Scheduled sale ($2k) by SVP, FINANCE AND ACCOUNTING under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.